MA56114A - Composés pour le traitement de troubles dépendant de la kinase - Google Patents

Composés pour le traitement de troubles dépendant de la kinase

Info

Publication number
MA56114A
MA56114A MA056114A MA56114A MA56114A MA 56114 A MA56114 A MA 56114A MA 056114 A MA056114 A MA 056114A MA 56114 A MA56114 A MA 56114A MA 56114 A MA56114 A MA 56114A
Authority
MA
Morocco
Prior art keywords
kinase
compounds
treatment
dependent disorders
disorders
Prior art date
Application number
MA056114A
Other languages
English (en)
Inventor
Lynne Canne Bannen
Minna Bui
Faming Jiang
Kin Tso
Yong Wang
Wei Xu
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MA56114A publication Critical patent/MA56114A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
MA056114A 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase MA56114A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962856920P 2019-06-04 2019-06-04

Publications (1)

Publication Number Publication Date
MA56114A true MA56114A (fr) 2022-04-13

Family

ID=71842789

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056114A MA56114A (fr) 2019-06-04 2020-06-03 Composés pour le traitement de troubles dépendant de la kinase

Country Status (10)

Country Link
US (1) US20230043835A1 (fr)
EP (1) EP3980404A1 (fr)
JP (1) JP2022535108A (fr)
CN (1) CN114040912A (fr)
AR (1) AR119069A1 (fr)
AU (1) AU2020289324A1 (fr)
CA (1) CA3139156A1 (fr)
MA (1) MA56114A (fr)
TW (1) TW202110806A (fr)
WO (1) WO2020247418A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3088200A1 (fr) * 2018-01-26 2019-08-01 Exelixis, Inc. Composes destines au traitement de troubles dependant de la kinase
CN114573553B (zh) * 2022-01-27 2023-11-10 广州六顺生物科技有限公司 杂芳环类衍生物及其制备方法和应用
CN114605391B (zh) * 2022-02-21 2024-01-26 广州六顺生物科技股份有限公司 喹喔啉类衍生物及其制备方法和应用
CN116271008A (zh) * 2022-12-30 2023-06-23 广东天普生化医药股份有限公司 含有安柯瑞和卡瑞利珠单抗的药物组合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1871417B1 (fr) 2005-04-15 2013-09-11 Precision Biologics, Inc. Anticorps monoclonaux recombinés et antigènes correspondants contre les cancers du colon et du pancréas
EP2423208A1 (fr) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Composants actifs pharmaceutiquement en tant qu'inhibiteurs Axl
US8664244B2 (en) * 2010-09-12 2014-03-04 Advenchen Pharmaceuticals, LLC Compounds as c-Met kinase inhibitors
EP2903641A2 (fr) 2012-10-04 2015-08-12 Dana-Farber Cancer Institute, Inc. Anticorps monoclonaux humains anti pd-l1 et procédés d'utilisation
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
CN104817497B (zh) * 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
CN106279147A (zh) * 2015-05-21 2017-01-04 中国科学院上海药物研究所 一种吡啶并氮杂环化合物及其制备方法和用途
CN110437145A (zh) * 2016-09-13 2019-11-12 上海翔锦生物科技有限公司 酪氨酸激酶抑制剂及其应用
KR20200100120A (ko) * 2017-12-20 2020-08-25 앤젝스 파마수티컬, 인크. 멀티키나제 억제제로서의 카바메이트 및 우레아 화합물
CA3088200A1 (fr) * 2018-01-26 2019-08-01 Exelixis, Inc. Composes destines au traitement de troubles dependant de la kinase

Also Published As

Publication number Publication date
CN114040912A (zh) 2022-02-11
AR119069A1 (es) 2021-11-24
AU2020289324A1 (en) 2021-12-16
EP3980404A1 (fr) 2022-04-13
US20230043835A1 (en) 2023-02-09
WO2020247418A1 (fr) 2020-12-10
TW202110806A (zh) 2021-03-16
JP2022535108A (ja) 2022-08-04
CA3139156A1 (fr) 2020-12-10

Similar Documents

Publication Publication Date Title
MA51673A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA56114A (fr) Composés pour le traitement de troubles dépendant de la kinase
MA55974A (fr) Composés triaryles pour le traitement de maladies pd-l1
MA49279A (fr) Compositions d'anticorps optimisées pour le traitement de troubles oculaires
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA44083A (fr) Composés de biarylmonobactame pour le traitement d'infections bactériennes
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
MA51829A (fr) Inhibiteurs de la voie jak1 pour le traitement de troubles liés aux cytokines
MA51916A (fr) Compositions pour le traitement de la dégénérescence maculaire liée à l'âge humide
MA51738A (fr) Composés pour le traitement de la douleur
MA42953A (fr) Composés et compositions pour le traitement de troubles oculaires
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
MA47719A (fr) Esketamine pour le traitement de la dépression
MA51046A (fr) Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
MA55148A (fr) Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
MA46099A (fr) Composés pour le traitement de maladies associées à un dysfonctionnement mitochondrial
MA52415A (fr) Dérivés de triazine pour le traitement de maladies associées à des neurotrophines
MA52761A (fr) Schéma posologique destiné au traitement de troubles liés à la pi3k
MA50391A (fr) Nouveaux composés et compositions pharmaceutiques associées pour le traitement de troubles inflammatoires
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
MA50069A (fr) Dérivés 1-(4-(isoxazol-5-yl)-1h-pyrazol-1-yl)-2-méthylpropan-2-ol et composés similaires en tant qu'inhibiterus il-7 et ifn-gamma pour le traitement de maladies autoimmune et inflammation chronique
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA51679A (fr) Composés destinés au traitement de troubles dépendant de la kinase
MA53664A (fr) Composés destinés au traitement de certaines leucémies